Submitted: 05 Jan 2019
Accepted: 29 Mar 2019
First published online: 18 Apr 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2019;8(3):204-210.
doi: 10.15171/jrip.2019.38
  Abstract View: 248
  PDF Download: 196

Original

Serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and IL-17 levels are associated with disease activity in systemic lupus erythematosus patients with and without nephritis

Mohammadreza Nakhjavani 1 ORCiD, Sima Abediazar 2 ORCiD, Amir Ghorbanihaghjo 3 * ORCiD, Niloofar Esmaeili 1, Tala Pourlak 4 ORCiD, Sepideh Zununi Vahed 2 ORCiD

1 Department of Rheumatology, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding author: Amir Ghorbanihaghjo, Email: Email: ghorbaniamir@hotmail.com

Article

Introduction: Lupus nephritis (LN) is one of the most severe signs of systemic lupus erythematosus (SLE) and rapid diagnosis of kidney damage remains an important concern for LN.

Objectives: The aim of this study was to investigate the association of the serum levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and interleukin 17 (IL-17) with SLE severity, renal involvement, and other clinical manifestations in lupus patients.

Patients and Methods: In order to determine a better biomarker for the detection of renal damage, this study evaluated the ability of serum TWEAK (sTWEAK) and IL-17 in lupus patients with (n=25) and without (n=25) nephritis and healthy controls (n=39). Moreover, it compared the levels of these cytokines with disease activity and chronicity as well as traditional serum markers including complement C3 and C4, creatinine, and proteinuria in lupus patients.

Results: Increased levels of sTWEAK and IL-17 were observed in SLE and LN groups compared to healthy controls and non-LN groups, respectively. Significant positive associations were observed between serum TWEAK and IL-17 levels and systemic lupus erythematosus disease activity index (SLEDAI), proteinuria, nephritis activity index, and some clinical manifestations (P<0.05). Discriminating the ability of the studied cytokines were not better than the utility of any markers individually.

Conclusion: The serum levels of TWEAK and IL-17 in the SLE and LN groups were significantly higher than the control group and both markers were indicative of the renal disease severity; therefore, they could possibly indicate renal involvement in the lupus patients.

Implication for health policy/practice/research/medical education:

A reliable marker that can reveal the renal disease activity in lupus patients is desirable. In the present study, we evaluated the diagnostic values of serum tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and IL-17 in serum samples of lupus patients with and without nephritis and healthy controls.

Please cite this paper as: Nakhjavani MR, Abediazar S, Ghorbanihaghjo A, Esmaeili N, Pourlak T, Zununi Vahed S. Serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and IL-17 levels are associated with disease activity in systemic lupus erythematosus patients with and without nephritis. J Renal Inj Prev. 2019;8(3):204-210. DOI: 10.15171/jrip.2019.38.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 248

Your browser does not support the canvas element.


PDF Downloaded: 196

Your browser does not support the canvas element.